A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

686

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer

Interventions

BIOLOGICAL: Sacituzumab Tirumotecan
DRUG: Pemetrexed
BIOLOGICAL: Tisotumab Vedotin
DRUG: Topotecan
DRUG: Vinorelbine
DRUG: Gemcitabine
DRUG: Irinotecan

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]
[object Object]